News | October 04, 2011

Roche to Expand Coagulation Testing Portfolio, Develop New Systems

October 4, 2011 – Roche announced plans today to expand its coagulation testing product line in North America beyond physician offices and outpatient clinics with the development of a full line of coagulation analyzers for hospital and reference laboratories. The new line is expected to be introduced in the United States and Canada in 2014, subject to regulatory approval and other requirements.

Roche Diagnostics is a market leader in coagulation (blood clotting) testing at the point-of-care, offering the CoaguChek line of hand-held meters for use by healthcare professionals and patients. The new line of analyzers for the central coagulation lab, which will be marketed under Roche's cobas brand, is expected to include three platforms that address a range of customer needs, from low-volume testing to the high-throughput demands of commercial laboratories, along with a complete menu of coagulation assays.

The announcement follows the statement that, effective Jan. 1, 2012, Roche Diagnostics and Diagnostica Stago will pursue separate paths in laboratory coagulation in territories where Roche distributes the Stago line of lab coagulation analyzers. Roche does not currently distribute Stago products in the United States or Canada, so the introduction of the new lab coagulation product line will represent a significant move into a new market for Roche in both countries.

Laboratory coagulation is estimated to be the fifth largest market in professional diagnostics worldwide, representing approximately $1.3 billion in sales in 2010 and having a projected annual growth rate of 5.1 percent over the next five years.

For more information: www.roche.com

 

Related Content

News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Overlay Init